Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CB-5083 |
Synonyms | |
Therapy Description |
CB-5083 binds to and inhibits valosin-containing protein (VCP, p97) to activate the unfolded protein response, resulting in ER stress, apoptosis, and decreased tumor cell proliferation (PMID: 28878026, PMID: 29314493, PMID: 30606672, PMID: 30591537, PMID: 32655822). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CB-5083 | CB5083|CB 5083 | CB-5083 binds to and inhibits valosin-containing protein (VCP, p97) to activate the unfolded protein response, resulting in ER stress, apoptosis, and decreased tumor cell proliferation (PMID: 28878026, PMID: 29314493, PMID: 30606672, PMID: 30591537, PMID: 32655822). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02243917 | Phase I | CB-5083 | A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02223598 | Phase I | CB-5083 CB-5083 + Dexamethasone | A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102) | Terminated | USA | CAN | 0 |